News | Catheters | August 09, 2017

Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution

Roxwood’s anchoring catheters and microcatheters will join Abbott’s other cath lab offerings

Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution

August 9, 2017 — Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of Roxwood products in the United States.

Roxwood's anchoring catheters (CenterCross Ultra, MultiCross) and microcatheters (MicroCross) offer minimally invasive platforms for physicians to percutaneously treat patients with chronic blockages by facilitating guidewire access across the blockage, often times averting an invasive bypass procedure. Roxwood's anchoring and microcatheters will join Abbott's other product offerings including the Xience drug-eluting stent and the Optis integrated optical coherence tomography system.

Percutaneous coronary interventions (PCI) are considered complex when patients have other chronic conditions such as diabetes or advanced kidney disease, when multiple vessels are involved, or if a vessel is severely blocked. The majority of PCIs performed today in the United States are considered complex in nature.

For more information: www.roxwoodmedical.com

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init